Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections.
about
Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infectionsIndividualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.Evaluation of a potential tigecycline-warfarin drug interaction.Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies.Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia.Multi-drug-resistant Klebsiella pneumoniae pancreatitis: a new challenge in a serious surgical infection.Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia.Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecyclineFrequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statistics.Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.Pharmacokinetics and pharmacodynamics of antibacterial agents.Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.Efficacy and safety of tigecycline: a systematic review and meta-analysis.Pharmacokinetic and pharmacodynamic evaluation of tigecycline.Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections.In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model.Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae.The therapeutic effect of tigecycline, unlike that of Ceftazidime, is not influenced by whether the Klebsiella pneumoniae strain produces extended-spectrum β-lactamases in experimental pneumonia in rats.Clinical and microbiological efficacy of tigecycline for complicated skin-soft-tissue and intra-abdominal infections in a Turkish university hospital.Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance.A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics.Determination of tigecycline in human plasma by LC-MS/MS and its application to population pharmacokinetics study in Chinese patients with hospital-acquired pneumonia.
P2860
Q33676144-28B954FF-A64B-4323-BEBB-6C74052210D1Q34274190-F818E714-2EFA-405B-93C6-C596EEDC2001Q34309574-0F126965-4811-476A-B06B-425D28DFCE36Q34513298-A27A5D85-0140-4816-A6E6-7C14C9B62B8FQ34593514-8F3E7285-36A4-4038-AD28-EAAB9A081DA4Q34803735-C1AC156E-CCFE-4EEE-B935-738AF81CF08FQ35026616-2AAF5D95-6610-4031-870A-BDB1C24591F2Q35376617-CD17D59A-D9C4-467E-A8B7-71DCEFCD76F4Q35666608-1BEFD89E-CCC3-46F4-B4F1-4AC362031BF9Q35689185-33ADE62D-10DE-4FE9-923F-8020B72BCBEDQ35806456-C4FCCCFF-490D-4867-9009-2E7B95BE6F31Q36757628-C47469EF-3813-43D4-A4BB-65CA54C0AB0AQ36911111-9E77B5B2-B61F-4BF6-9AC7-EA8B5D0CB9EFQ37115690-BF28C4E0-48C8-4E8A-8D8C-04E3BCD83AABQ37247732-95B96D4A-0045-483E-AF6A-2F5BC399A359Q37891606-8D888C3D-5C2E-4428-BB91-63365DDE74B2Q37940546-712CE05C-BF24-4529-9110-5AC692E28CFFQ38100704-7605BFBE-C508-4517-A170-FD54A3A3F9EBQ40175198-9ABA258C-BD49-476D-8F20-0D4C9C3B3359Q40248088-3C1E266C-AE69-4371-AECE-05A8845472FFQ40533542-019F2A35-C82B-4C85-934A-820B06845FB3Q41787127-DEDE6505-9318-434D-834F-DD0655116FE3Q42262776-B2FAE374-D80B-4E7A-9848-705B438D9462Q46133387-D47756E2-E19D-4DED-9E79-CF866853C8D1Q46699478-26CFC0AA-2DA3-49B4-9D05-3DBCF95DB7F8Q47983248-836F371F-6ADC-4F03-99B2-8D0EE6DD5B8A
P2860
Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Exposure-response analyses of ...... ed intra-abdominal infections.
@ast
Exposure-response analyses of ...... ed intra-abdominal infections.
@en
type
label
Exposure-response analyses of ...... ed intra-abdominal infections.
@ast
Exposure-response analyses of ...... ed intra-abdominal infections.
@en
prefLabel
Exposure-response analyses of ...... ed intra-abdominal infections.
@ast
Exposure-response analyses of ...... ed intra-abdominal infections.
@en
P2093
P2860
P356
P1476
Exposure-response analyses of ...... ed intra-abdominal infections.
@en
P2093
Ambrose PG
Babinchak T
Cirincione BB
Ellis-Grosse EJ
Meagher AK
Passarell JA
Van Wart SA
P2860
P304
P356
10.1128/AAC.00813-07
P407
P577
2007-10-22T00:00:00Z